BioTechniques News
Maddy Chapman
Here, we highlight new chromatography and mass spectrometry technologies, a partnership facilitating single-molecule mutation sequencing for toxicology testing and funding that will advance early-stage ovarian cancer and rare disease research.
Products
Introducing isotope ratio analysis mode
Thermo Fisher Scientific (MA, USA) has introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analysis accessible to more laboratories and researchers worldwide.
Read the full release here >>>
Simplifying downstream process-scale chromatography
Bio-Rad Laboratories (CA, USA) has announced the launch of prepacked process-scale Foresight™ Pro chromatography columns packed with Bio-Rad’s scalable Nuvia™ chromatography resins, for downstream process-scale chromatography applications throughout the various stages in biological drug development and manufacturing.
Read the full release here >>>
Going native: inside the mind behind some of mass spectrometry’s greatest developments
We caught up with Albert Heck, who pioneered several technological developments in MS, to discuss his work on native MS, his contributions to cross-linking MS, and to get his advice for working with these innovative techniques.
Partnerships
Relocating a leading innovation engine for pharma
BioMed X (Heidelberg, Germany) has announced the relocation of its global headquarters to LAB22 at Heidelberg Innovation Park, together with the launch of a global partnership with BioLabs (MA, USA), a provider of shared laboratory infrastructure for life science innovators.
Read the full release here >>>
Facilitating single-molecule mutation sequencing
Toxys (Oegstgeest, Netherlands), an innovative toxicology testing company, and Mutagentech (NY, USA), a biotechnology company specialized in advanced genomic technologies, have announced a strategic collaboration that will make Mutagentech’s proprietary single-molecule mutation sequencing technology available through Toxys’ contract research services.
Read the full release here >>>
How long-read sequencing is scaling beyond the specialist lab
Aaron Wenger, Principal Scientist – Bioinformatics at PacBio, explores how advances in accuracy, throughput and cost are making long-read sequencing more accessible at scale.
People & publications
Strengthening the Oxford Nanopore team
Oxford Nanopore (UK) has announced the appointment of David Miller as Chief Development and Product Officer and Conor McKechnie as Chief Marketing and Communications Officer, joining on 1 September and 1 October, respectively. Together, these appointments strengthen Oxford Nanopore’s leadership team, bringing greater alignment between product development, market positioning and commercial execution.
Read the full release here >>>
Publishing a comprehensive guide for designing preclinical oncology programs
Altogen Labs (TX, USA) published a comprehensive framework for xenograft model selection and standardization in JoVE, a practical guide to designing preclinical oncology programs from early efficacy through Investigational New Drug- enabling safety studies. The framework addresses preclinical model selection and the integration of cell line-derived xenograft, patient-derived xenograft, orthotopic, humanized and organoid-derived platforms into oncology research workflows, where each answers a different question at a different stage of development.
Read the full release here >>>
Funding high-risk, high-reward biomedical research
Probably Genetic (CA, USA), the AI platform powering the research, diagnosis and treatment of genetic diseases, has been awarded up to US$10 million from the Advanced Research Projects Agency for Health (ARPA-H; MD, USA), a USA federal agency within the Department of Health and Human Services that funds high-risk, high-reward and transformative biomedical research. As part of ARPA-H’s Rare Disease AI/ML for Precision Integrated Diagnostics (RAPID) program, Probably Genetic will leverage and build upon its rich dataset to aggregate data directly from patients and caregivers, revealing patterns that will dramatically reduce the diagnostic odyssey faced by rare disease patients. Beyond diagnosis, this data will form the backbone of multi-omic phenotype models that link real-world evidence to disease biology and give drug developers insights needed to identify targets, stratify patients and design clinical trials.
Read the full release here >>>
Developing therapies that reprogram cancer biology: new preclinical data just in
Kazia Therapeutics (Sydney, Australia), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, has announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden – the total amount of cancer in the body – by 52% in microsatellite stable / proficient mismatch repair colorectal cancer.
Read the full release here >>>
Advancing early-stage ovarian cancer research
The Mike & Patti Hennessy Foundation (NJ, USA) has announced a grant to City of Hope (CA, USA), one of the largest and most advanced cancer research and treatment organizations in the country, to advance early-stage research aimed at detecting ovarian cancer earlier. The grant is part of the Mike & Patti Hennessy Foundation’s Ovarian Cancer Prevention & Early Detection Initiative, a significant, multi-year commitment to fund research and clinical work in the earliest and most underfunded part of the ovarian cancer continuum.
Read the full release here >>>
This article is a collection of rehosted press releases, each linked above. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
The post The biotech bi-weekly: designing preclinical oncology programs, mass spectrometers with an isotope ratio analysis mode and single-molecule mutation sequencing appeared first on BioTechniques.
Powered by WPeMatico